Skip to main content
# Title Research Member Research Year
81 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Dr. Tarek Mohamed Abdel Moneim Mohamed Elsaba Ahmed 2018
82 Flowcytometric CD135 Expression
and its Impact on Pediatric Acute
Lymphoblastic Leukemia at South Egypt
Cancer Institute
Dr. Azaa Shibl Sayed Mahmoud 2018
83 Risk-Adapted, Combined-Modality Therapy for
Unfavorable Pediatric Hodgkin Lymphom
Prof. Amany Mohamed Ali Ahmed 2018
84 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Dr. Samar Muhammad mansour 2018
85 Flowcytometric CD135 Expression
and its Impact on Pediatric Acute
Lymphoblastic Leukemia at South Egypt
Cancer Institute
Prof. Heba Abdel-Razik Sayed Hussein 2018
86 Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources Prof. Heba Abdel-Razik Sayed Hussein 2018
87 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Dr. Shaimaa / Elsayyed Youssef / Ahmed 2018
88 Bloodstream Infections in Febrile Neutropenic
Pediatric Cancer Patients: Microbiological and
Sepsis Biomarkers Insight
Dr. Khaled Fathy Riad Osman 2018
89 Myocardial Changes in Childhood Cancer Patients Treated with Anthracyclines Dr. Khaled Fathy Riad Osman 2017
90 P-458 Pain Experience Profile in Children with Cancer: Prospective Analysis of 2216 Treatment Days in a Developing Country Dr. Khaled Fathy Riad Osman 2017